Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
Despite substantial progress in confronting the global HIV-1 epidemic since its inception in the 1980s, better approaches for both treatment and prevention will be necessary to end the epidemic and remain a top public health priority. Antiretroviral therapy (ART) has been effective in extending lives, but at a cost of lifelong adherence to treatment. Broadly neutralizing antibodies (bNAbs) are directed to conserved regions of the HIV-1 envelope glycoprotein trimer (Env) and can block infection if present at the time of viral exposure. The therapeutic application of bNAbs holds great promise, and progress is being made toward their development for widespread clinical use. Compared to the current standard of care of small molecule-based ART, bNAbs offer: (1) reduced toxicity; (2) the advantages of extended half-lives that would bypass daily dosing requirements; and (3) the potential to incorporate a wider immune response through Fc signaling. Recent advances in discovery technology can enable system-wide mining of the immunoglobulin repertoire and will continue to accelerate isolation of next generation potent bNAbs. Passive transfer studies in pre-clinical models and clinical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and achieving viral suppression.
These studies have helped to define the window of opportunity for optimal intervention to achieve viral clearance, either using bNAbs alone or in combination with ART. None of these advances with bNAbs would be possible without technological advancements and expanding the cohorts of donor participation. Together these elements fueled the remarkable growth in bNAb development. Here, we review the development of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal models and early clinical trials, and innovations to optimize their clinical potential through efforts to extend half-life, maximize the contribution of Fc effector functions, preclude escape through multiepitope targeting, and the potential for sustained delivery.
Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers
Aim: In Germany, the willingness to be vaccinated against COVID-19 is rather low among medical staff. We collected data on symptoms, antibody titers and vaccination readiness from clinic employees at a municipal clinic who had already been through a COVID-19 infection (asymptomatic to moderate). We also examined the antibody titers for their possible importance as an individual decision-making aid with regard to vaccination.
Method: 200 employees of our municipal clinics were included in the study. COVID-19 antibody determination was performed using an ELISA (EUROIMMUN™, PerkinElmer, Inc. Company). The participants were given an anonymous questionnaire containing anthropometrical issues, symptoms of the infection and questions concerning the vaccination decision. Finally, the antibody levels were reported to the participants and the attitude towards a vaccination was reevaluated.
Results: In all 200 participants who had already gone through a COVID-19 infection, 75 employees were in favor of a vaccination (37.5%), 96 were opposed to vaccination (48%), and 29 were undecided (14.5%). In the different occupational groups, the positive trend in terms of willingness to be vaccinated was highest among physicians and is least among nurses. The antibody results showed considerable variation in titer levels and therefore did not correlate with disease severity in asymptomatic to moderately ill persons. We also observed a pro-vaccination trend with increasing age of the participants. The specifically-asked symptom of cutaneous hyperesthesia during COVID-19 infection occurred in 5% of the participants.
Conclusion: In medical personnel who had already suffered from a COVID-19 infection, the willingness to receive a vaccination tends to be highest among physicians, and lowest in nurses, and increases with age. For the vast majority of those affected, knowledge of the antibody titers only reinforces the vaccination decision made beforehand and thus does not contribute to a change in vaccination decision. The specifically-requested symptom of cutaneous hyperesthesia during COVID-19 infection was unexpectedly frequent.
Engineering a novel IgG-like bispecific antibody against enterovirus A71
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection. The development of monoclonal antibodies (mAbs) has demonstrated promise as a novel therapy for the prevention and treatment of infectious diseases. Several medical conditions have been treated using bispecific or multi-specific antibodies that recognize two or more distinct epitopes simultaneously. However, bispecific or multi-specific antibodies often encounter protein expression and product stability problems.
In this study, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral activity compared with E18 or F1. Additionally, E18-F1 not only improved survival rate, but also reduced clinical signs in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a lethal dose of EVA71. Altogether, our results reveal that E18-F1 is a simple format bispecific antibody with promising antiviral activity for EVA71.
Myelin Oligodendrocyte Glycoprotein-antibody-associated Disorder Presenting with Corticomeningeal Encephalitis prior to the Onset of Optic Neuritis
We herein report a case of myelin oligodendrocyte glycoprotein-antibody-associated disorder (MOG-AD) presenting with corticomeningeal encephalitis. The patient exhibited oral ulceration, a mild impairment of consciousness, fever, nausea, nuchal rigidity, positivity for human leukocyte antigen type B51, and neutrophil-dominant pleocytosis and interleukin-6 level in cerebrospinal fluid (CSF). Magnetic resonance imaging (MRI) revealed a right temporal lesion with leptomeningeal gadolinium enhancement.
The initial diagnosis was neuro-Behçet’s disease presenting with meningoencephalitis; however, a cell-based assay detected anti-MOG antibody in the serum and CSF and the patient also experienced bilateral optic neuritis. After administering steroid therapy, his neurologic symptoms and CSF abnormalities improved along with the disappearance of gadolinium enhancement and the lesion on MRI. This case suggests that MOG-AD may present with corticomeningeal encephalitis prior to the onset of optic neuritis.
Recombinant Bothrops atrox Disintegrin batroxostatin | |||
CSB-EP325595BUU | Cusabio | 10062 mg | Ask for price |
Recombinant Bothrops atrox Thrombin-like enzyme batroxobin | |||
CSB-EP356422BUU | Cusabio | 11904 mg | Ask for price |
Recombinant Bothrops atrox Zinc metalloproteinase atroxlysin-1 | |||
CSB-EP307733BUU | Cusabio | 10234 mg | Ask for price |
Recombinant Bothrops jararaca Zinc metalloproteinase-disintegrin-like botrocetin, partial | |||
CSB-EP325199BUW | Cusabio | 6923 mg | Ask for price |
Rabbit Anti-Snake VEGF-F | |||
105-PA01 | Angio Proteomie | 100ug | EUR 240 |
Snake Venom Phospholipase A2 Purified Lyophilized | |||
IDBRPLA2LY1MG | Innovative research | each | EUR 119 |
Description: Snake Venom Phospholipase A2 Purified Lyophilized |
Snake Venom Phosphodiesterase I Purified Lyophilized | |||
IDBRPDEILY100UN | Innovative research | each | EUR 151 |
Description: Snake Venom Phosphodiesterase I Purified Lyophilized |
Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 | |||
1-CSB-EP330325DYB | Cusabio |
|
|
Description: Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 expressed in E.coli |
Custom Testing of Samples for Antibodies Snake Venom (anti-venins from Horse/Sheep) by ELISA | |||
570-100-CUX | Alpha Diagnostics | Custom | Ask for price |
Recombinant Crotalus atrox Snake venom serine protease catroxase-2 | |||
CSB-YP854470DYC | Cusabio | 6937 mg | Ask for price |
Recombinant Crotalus atrox Snake venom serine protease catroxase-2 | |||
CSB-BP854470DYC | Cusabio | 7642 mg | Ask for price |
Recombinant Crotalus atrox Snake venom serine protease catroxase-2 | |||
RPC27424-100ug | Biomatik Corporation | 100ug | EUR 1544.5 |
Recombinant Crotalus atrox Snake venom serine protease catroxase-2 | |||
RPC27424-1mg | Biomatik Corporation | 1mg | EUR 3933.6 |
Recombinant Crotalus atrox Snake venom serine protease catroxase-2 | |||
RPC27424-20ug | Biomatik Corporation | 20ug | EUR 580.8 |
Recombinant Crotalus atrox Snake venom serine protease catroxase-2 | |||
RPC28372-100ug | Biomatik Corporation | 100ug | EUR 863.2 |
Recombinant Crotalus atrox Snake venom serine protease catroxase-2 | |||
RPC28372-1mg | Biomatik Corporation | 1mg | EUR 3462 |
Recombinant Crotalus atrox Snake venom serine protease catroxase-2 | |||
RPC28372-20ug | Biomatik Corporation | 20ug | EUR 479.6 |
Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 | |||
CSB-EP330325DYB | Cusabio | 2971 mg | Ask for price |
Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 | |||
AP77219 | SAB | 1mg | EUR 2826 |
Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 | |||
RPC22529-100ug | Biomatik Corporation | 100ug | EUR 721.6 |
Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 | |||
RPC22529-1mg | Biomatik Corporation | 1mg | EUR 2884.7 |
Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 | |||
RPC22529-20ug | Biomatik Corporation | 20ug | EUR 448.1 |
Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin | |||
1-CSB-EP606027NAH | Cusabio |
|
|
Description: Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin expressed in E.coli |
Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin | |||
CSB-EP606027NAH | Cusabio | 3683 mg | Ask for price |
Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin | |||
AP74342 | SAB | 1mg | EUR 2826 |
Anti- VEGF antibody | |||
FNab09933 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against VEGF |
anti- VEGF antibody | |||
FNab09391 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against VEGF |
Anti-Human VEGF | |||
GWB-BIG9B7 | GenWay Biotech | 500ug | Ask for price |
Anti-VEGF/VEGF164 Antibody | |||
A00045-1 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug | |||
7422-MSM1-P1 | EnQuireBio | 100ug | EUR 513.6 |
VEGF-A(VEGF/1063) Antibody | |||
BNCAP1063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNCAP1063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNCH1063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNCH1063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC701063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC701063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC811063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC811063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC801063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC801063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC551063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC551063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC431063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC431063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC611063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC611063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC051063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNC051063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNCA1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNCP1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody | |||
BNCR1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL |
Anti-Rat VEGF Antibody | |||
TA328599 | Origene Technologies GmbH | 100 µg | Ask for price |
Anti-VEGF/Vegfa Antibody | |||
A00045 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-VEGF/Vegfa Antibody | |||
A00045-2 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-VEGF/VEGFA Antibody | |||
PB9071 | BosterBio | 100ug/vial | EUR 400.8 |
VEGF-F / svVEGF rabbit polyclonal antibody, Purified | |||
AP26033PU-L | Origene Technologies GmbH | 200 µg | Ask for price |
VEGF-F / svVEGF rabbit polyclonal antibody, Purified | |||
AP26033PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit anti VEGF-C (rat) | |||
104-PA10S | Angio Proteomie | 100ug | EUR 240 |
Rabbit anti VEGF-D (rat) | |||
104-PA12 | Angio Proteomie | 100ug | EUR 240 |
VEGF Rabbit Polyclonal Antibody(VEGF) | |||
RA20266-100ul | Reed Biotech | 100 ul | EUR 298 |
VEGF Rabbit Polyclonal Antibody(VEGF) | |||
RA20266-50ul | Reed Biotech | 50 ul | EUR 198 |
Anti-Rat VEGF-A Antibody | |||
104-P15 | ReliaTech | 100 µg | EUR 245.7 |
Description: Rat VEGF (or VEGF-A) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothellial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase(flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant rat VEGF (isoform 164) is a 38.5 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Rat VEGF-C Antibody | |||
104-PA10 | ReliaTech | 200 µg | EUR 157.5 |
Description: VEGF-C, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-C is expressed in various tissues, but is not produced in peripheral blood lymphocytes. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-C may play a role in the formation of the venous and lymphatic vascular systems. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. Recombinant, fully processed rat VEGF-C is a 16-18 kDa non-disulfide linked homodimeric protein consisting of two 116 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition. |
Anti-Rat VEGF-D Antibody | |||
104-PA12S | ReliaTech | 100 µg | EUR 115.5 |
Description: Vascular endothelial growth factor D (VEGF-D), also known as C-fos induced growth factor (FIGF), is a vascular endothelial growth factor. This secreted protein is a member of the platelet derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and performs activities in angiogenesis, lymphangiogenesis, and endothelial cell growth. Human VEGF-D is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. It is structurally and functionally similar to VEGF-C, and is secreted as a non-covelent homodimer in a antiparallel fashion. VEGF-D undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. Like VEGFC, it may particularly be involed in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. |
Anti-Rat VEGF-C Antibody | |||
104-PABi10 | ReliaTech | 50 µg | EUR 157.5 |
Description: VEGF-C, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-C is expressed in various tissues, but is not produced in peripheral blood lymphocytes. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-C may play a role in the formation of the venous and lymphatic vascular systems. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. Recombinant, fully processed rat VEGF-C is a 16-18 kDa non-disulfide linked homodimeric protein consisting of two 116 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition. |
Anti-bovine VEGF-A PAb | |||
GWB-QIUF78 | GenWay Biotech | 1 kit | Ask for price |
Anti-bovine VEGF-A PAb | |||
GWB-W4HYD7 | GenWay Biotech | 1 kit | Ask for price |
Anti-equine VEGF-A PAb | |||
GWB-KI0037 | GenWay Biotech | 1 kit | Ask for price |
Rabbit anti VEGF-A (human) | |||
102-PA02S | Angio Proteomie | 100ug | EUR 240 |
Rabbit anti VEGF-A (human) | |||
102-PA03AG | Angio Proteomie | 50ug | EUR 240 |
Rabbit anti VEGF-A (mouse) | |||
103-PA03AG | Angio Proteomie | 50ug | EUR 297.6 |
Rabbit anti VEGF-A (mouse) | |||
103-PA03S | Angio Proteomie | 100ug | EUR 240 |
Anti-Human VEGF-A Antibody | |||
102-P91 | ReliaTech | 100 µg | EUR 245.7 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody | |||
102-P91G | ReliaTech | 100 µg | EUR 245.7 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody | |||
102-PA02 | ReliaTech | 200 µg | EUR 147 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. The antibody is against the N-terminus and will recognize all VEGF-A isoforms. |
Anti-Human VEGF-B Antibody | |||
102-PA72S | ReliaTech | 100 µg | EUR 126 |
Description: Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity. Five mammalian members, including VEGF-A, B, C, D and PlGF, have been identified. VEGF family members are disulfide-linked dimeric proteins that are important regulators of physiological and pathological vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-B is expressed in most tissues, especially in heart, skeletal muscle and pancreas. In many tissues, VEGF-B is coexpressed and can heterodimerize with VEGF. By alternative splicing, two isoforms of mature VEGF-B containing 167 or 186 amino acid (aa) residues exist. The two VEGF-B isoforms have identical amino-terminal cysteine knot VEGF homology domains but the carboxyl end of VEGF-B167 differs from that of VEGF-B186 by the presence of a highly basic cysteine-rich heparin binding domain. Whereas VEGF-B186 is a secreted diffusible protein, VEGF-B167 is sequestered into the cell matrix after secretion. Both VEGF-B isoforms bind VEGF receptor 1 (VEGFR-1), but not VEGFR-2 or VEGFR-3. On endothelial cells, ligation of VEGFR-1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1. VEGF-B167 and a proteolytically processed form of VEGF-B186 (VEGF-B127) also bind neuropilin1 (NP1), a type I transmembrane receptor for semaphorins/collapsins, ligands involved in neuron guidance (6). Besides VEGF-B, NP1 has been shown to bind PlGF-2, VEGF165 and VEGFR-1. The many interactions of NP1 with VEGF ligands and receptor suggest that NP1 may function as a regulator of angiogenesis. |
Anti-Human VEGF-A Antibody | |||
101-MBi60 | ReliaTech | 50 µg | EUR 173.25 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-C Antibody | |||
101-MBi89 | ReliaTech | 50 µg | EUR 189 |
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions. |
Anti-Mouse VEGF-A Antibody | |||
103-M57 | ReliaTech | 100 µg | EUR 399 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Mouse VEGF-A Antibody | |||
103-M57A | ReliaTech | 100 µg | EUR 399 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Mouse VEGF-B Antibody | |||
103-M62 | ReliaTech | 100 µg | EUR 399 |
Description: Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity. |
Anti-Mouse VEGF-D Antibody | |||
103-M66 | ReliaTech | 100 µg | EUR 399 |
Description: VEGF-D, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-D is highly expressed in the lung, heart, small intestine and fetal lung, and at lower levels in the skeletal muscle, colon, and pancreas. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-D may play a role in the formation of the venous and lymphatic vascular systems. It also participates in the growth and maintenance of differentiated lymphatic endothelium in adults. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. |
Anti-Mouse VEGF-A Antibody | |||
103-P36 | ReliaTech | 100 µg | EUR 245.7 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Mouse VEGF-A Antibody | |||
103-PA03 | ReliaTech | 200 µg | EUR 246.75 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Mouse VEGF-A Antibody | |||
103-PABi03 | ReliaTech | 50 µg | EUR 157.5 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Human VEGF-A Antibody | |||
101-M57 | ReliaTech | 100 µg | EUR 399 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody | |||
101-M60 | ReliaTech | 100 µg | EUR 173.25 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-B Antibody | |||
101-M62 | ReliaTech | 100 µg | EUR 399 |
Description: VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, helps regulate angiogenesis and vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains. |
Anti-Human VEGF-C Antibody | |||
101-M64 | ReliaTech | 100 µg | EUR 399 |
Description: VEGF-C, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-C is expressed in various tissues, but is not produced in peripheral blood lymphocytes. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-C may play a role in the formation of the venous and lymphatic vascular systems. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. Recombinant, fully processed human VEGF-C is a 13.5 kDa non-disulfide linked homodimeric protein consisting of two 116 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition. |
Anti-Human VEGF-D Antibody | |||
101-M66 | ReliaTech | 100 µg | EUR 399 |
Description: VEGF-D, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-D is highly expressed in the lung, heart, small intestine and fetal lung, and at lower levels in the skeletal muscle, colon, and pancreas. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-D may play a role in the formation of the venous and lymphatic vascular systems. It also participates in the growth and maintenance of differentiated lymphatic endothelium in adults. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. |
Anti-Human VEGF-A Antibody | |||
101-M855 | ReliaTech | 100 µg | EUR 399 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-B Antibody | |||
101-M856 | ReliaTech | 100 µg | EUR 399 |
Description: VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, helps regulate angiogenesis and vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains. |
Anti-Human VEGF-B Antibody | |||
101-M857 | ReliaTech | 100 µg | EUR 399 |
Description: VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, helps regulate angiogenesis and vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains. |
Anti-Human VEGF-B Antibody | |||
101-M858 | ReliaTech | 100 µg | EUR 399 |
Description: VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, helps regulate angiogenesis and vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains. |
Anti-Human VEGF-D Antibody | |||
101-M859 | ReliaTech | 100 µg | EUR 399 |
Description: VEGF-D, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-D is highly expressed in the lung, heart, small intestine and fetal lung, and at lower levels in the skeletal muscle, colon, and pancreas. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-D may play a role in the formation of the venous and lymphatic vascular systems. It also participates in the growth and maintenance of differentiated lymphatic endothelium in adults. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. |
Anti-Human VEGF-C Antibody | |||
101-M88 | ReliaTech | 100 µg | EUR 189 |
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions. |
Anti-Human VEGF-C Antibody | |||
101-M89 | ReliaTech | 100 µg | EUR 189 |
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions. |
Anti-Human VEGF-C Antibody | |||
101-M90 | ReliaTech | 100 µg | EUR 189 |
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions. |
Anti-Human VEGF-C Antibody | |||
101-M91 | ReliaTech | 100 µg | EUR 189 |
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions. |
Anti-mouse VEGF(Rat) Antibody | |||
Y052991 | ABM | 100 µg | EUR 695 |
mouse anti-human VEGF mAb | |||
E409C31-m100 | EnoGene | 100μL | EUR 395 |
Description: Available in various conjugation types. |
Rat Monoclonal anti-mouse VEGF 164 | |||
mAP-0009A | Angio Proteomie | 100ug | EUR 250 |
Anti-Human VEGF Purified Ab | |||
E16THU007-050 | EnoGene | 50Tests | EUR 145 |
Description: Available in various conjugation types. |
Anti-Human VEGF Purified Ab | |||
E16THU007-100 | EnoGene | 100Tests | EUR 225 |
Description: Available in various conjugation types. |
Mouse Monoclonal anti-human VEGF-165b | |||
hAP-0051 | Angio Proteomie | 100ug | EUR 250 |
Rabbit Anti-Human VEGF-B167 | |||
102-PA72 | Angio Proteomie | 100ug | EUR 240 |
Humanized anti-human VEGF antibody | |||
APT-0002 | Angio Proteomie | 1Service | Ask for price |
Rat Monoclonal anti-mouse VEGF | |||
mAP-0009 | Angio Proteomie | 100ug | EUR 250 |
Rabbit Anti-Human VEGF Polyclonal | |||
SPC-1291D | Stressmarq | 0.1ml | EUR 286 |
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is unconjugated. |
Rabbit Anti-Human VEGF Polyclonal | |||
SPC-1291D-A390 | Stressmarq | 0.1ml | EUR 340 |
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 390. |
Rabbit Anti-Human VEGF Polyclonal | |||
SPC-1291D-A488 | Stressmarq | 0.1ml | EUR 339 |
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 488. |
Rabbit Anti-Human VEGF Polyclonal | |||
SPC-1291D-A594 | Stressmarq | 0.1ml | EUR 339 |
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 594. |
Rabbit Anti-Human VEGF Polyclonal | |||
SPC-1291D-BI | Stressmarq | 0.1ml | EUR 334 |
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Biotin. |
Rabbit Anti-Human VEGF Polyclonal | |||
SPC-1291D-FITC | Stressmarq | 0.1ml | EUR 330 |
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to FITC. |
Mouse anti VEGF-A (#3) (human) | |||
101-M59 | Angio Proteomie | 100ug | EUR 297.6 |
Mouse anti VEGF-A (#3C5) (human) | |||
101-M56 | Angio Proteomie | 100ug | EUR 297.6 |
Mouse anti VEGF-A (#7G7) (human) | |||
101-M58 | Angio Proteomie | 100ug | EUR 297.6 |
VEGF-A(VEGF/1063), 1mg/mL | |||
BNUM1063-50 | Biotium | 50uL | EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
VEGF-A(VEGF/1063), 0.2mg/mL | |||
BNUB1063-100 | Biotium | 100uL | EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
VEGF-A(VEGF/1063), 0.2mg/mL | |||
BNUB1063-500 | Biotium | 500uL | EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
human anti-human VEGF mAb(1C) | |||
E4A09D12-A1C | EnoGene | 50ug | EUR 255 |
Description: Available in various conjugation types. |
human anti-human VEGF mAb(9D) | |||
E4A09D12-B9D | EnoGene | 50ug | EUR 255 |
Description: Available in various conjugation types. |
human anti-human VEGF mAb(46) | |||
E4A09D12-46 | EnoGene | 50ug | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human VEGF mAb(47) | |||
E4A09D12-47 | EnoGene | 50ug | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human VEGF mAb(52) | |||
E4A09D12-52 | EnoGene | 50ug | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human VEGF mAb(57) | |||
E4A09D12-57 | EnoGene | 50ug | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human VEGF mAb(6A) | |||
E4A09D12-6A | EnoGene | 50ug | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human VEGF mAb(6C) | |||
E4A09D12-6C | EnoGene | 50ug | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human VEGF mAb(6E) | |||
E4A09D12-6E | EnoGene | 50ug | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Rabbit anti VEGF-A pan (human) | |||
102-PA03S | Angio Proteomie | 100ug | EUR 240 |
Anti-Orf Virus VEGF-E Antibody | |||
102-PA70 | ReliaTech | 50 µg | EUR 115.5 |
Description: A DNA sequence encoding the mature variant of ov-VEGF-E isolate D1701 was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight Cysteine residues of the central Cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins. Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E cannot bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR. |
VEGF/ Rat VEGF ELISA Kit | |||
ELA-E0143r | Lifescience Market | 96 Tests | EUR 1063.2 |
VEGF antibody | |||
10-2585 | Fitzgerald | 250 ug | EUR 590.4 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody | |||
10-2586 | Fitzgerald | 100 ug | EUR 289.2 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody | |||
10R-7735 | Fitzgerald | 500 ug | EUR 678 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody | |||
10R-V101ax | Fitzgerald | 100 ug | EUR 571.2 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody | |||
10R-V101b | Fitzgerald | 200 ug | EUR 805.2 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody | |||
10R-V109A | Fitzgerald | 500 ug | EUR 240 |
Description: Mouse monoclonal VEGF antibody |
VEGF Antibody | |||
48707 | SAB | 100ul | EUR 499 |
VEGF Antibody | |||
48707-100ul | SAB | 100ul | EUR 399.6 |
VEGF Antibody | |||
48707-50ul | SAB | 50ul | EUR 286.8 |
VEGF Antibody | |||
E18-5131-1 | EnoGene | 50μg/50μl | EUR 145 |
Description: Available in various conjugation types. |
VEGF Antibody | |||
E18-5131-2 | EnoGene | 100μg/100μl | EUR 225 |
Description: Available in various conjugation types. |
VEGF Antibody | |||
E8ER30607 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
VEGF Antibody | |||
E8RT1649 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
VEGF Antibody | |||
E90126 | EnoGene | 100ug | EUR 255 |
Description: Available in various conjugation types. |
VEGF Antibody | |||
GWB-2184EB | GenWay Biotech | 0.1 mg | Ask for price |
VEGF Antibody | |||
E3M00036 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
VEGF Antibody | |||
E3M00102 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
VEGF Antibody | |||
E301007 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
VEGF antibody | |||
70-VR20 | Fitzgerald | 50 ug | EUR 312 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF Antibody | |||
5363-100 | Biovision | each | EUR 398.4 |
VEGF Antibody | |||
5363-30T | Biovision | each | EUR 175.2 |
VEGF Antibody | |||
5365-100 | Biovision | each | EUR 379.2 |
VEGF Antibody | |||
5365-30T | Biovision | each | EUR 175.2 |
VEGF antibody | |||
70R-VG001 | Fitzgerald | 100 ug | EUR 312 |
Description: Affinity purified Goat polyclonal VEGF antibody |
VEGF antibody | |||
70R-VR001x | Fitzgerald | 50 ug | EUR 312 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
70R-VR003 | Fitzgerald | 50 ug | EUR 312 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
70R-VR004 | Fitzgerald | 50 ug | EUR 312 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
70R-VR006 | Fitzgerald | 50 ug | EUR 312 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
70R-13764 | Fitzgerald | 100 ug | EUR 578 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
70R-11863 | Fitzgerald | 100 ul | EUR 375 |
Description: Goat polyclonal VEGF antibody |
VEGF antibody | |||
70R-11864 | Fitzgerald | 100 ug | EUR 343 |
Description: Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
70R-12327 | Fitzgerald | 100 ug | EUR 364 |
Description: Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
70R-12328 | Fitzgerald | 100 ug | EUR 343 |
Description: Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
70R-12329 | Fitzgerald | 100 ug | EUR 343 |
Description: Rabbit polyclonal VEGF antibody |
VEGF antibody | |||
CAF50370-100ug | Biomatik Corporation | 100ug | EUR 338 |
VEGF antibody | |||
CAF50643-100ug | Biomatik Corporation | 100ug | EUR 364 |
VEGF Antibody | |||
ABF5131 | Lifescience Market | 100 ug | EUR 525.6 |
VEGF Antibody | |||
GWB-AA0FA3 | GenWay Biotech | 0.5 ml | Ask for price |
VEGF, Antibody | |||
GWB-5F48B1 | GenWay Biotech | 7 ml | Ask for price |
VEGF Antibody | |||
GWB-7D2F87 | GenWay Biotech | 0.1 mg | Ask for price |
VEGF Antibody | |||
GWB-E45680 | GenWay Biotech | 0.5 ml | Ask for price |
VEGF Antibody | |||
GWB-E54BC7 | GenWay Biotech | 0.25 ml | Ask for price |
VEGF Antibody | |||
GWB-88861F | GenWay Biotech | 0.5 ml | Ask for price |
VEGF, Antibody | |||
GWB-F61EF9 | GenWay Biotech | 7 ml | Ask for price |
VEGF, Antibody | |||
GWB-C4E434 | GenWay Biotech | 1 ml | Ask for price |
VEGF Antibody | |||
R31500 | NSJ Bioreagents | 100 ug | EUR 356.15 |
Description: VEGF is the only mitogen that specifically acts on endothelial cells. It may be a major regulator of tumor angiogenesis in vivo. It is structurally related to platelet-derived growth factor. VEGF shares homology with the PDGF A chain and B chain, including conservation of all 8 cysteines found in PDGFA and PDGFB. VEGF gene contains 8 exons. VEGF induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. And this gene also can regulate haematopoietic stem cell survival by an internal autocrine loop mechanism. What’s more, it also stimulates neurogenesis in vitro and in vivo. |
VEGF antibody | |||
PAab09933 | Lifescience Market | 100 ug | EUR 463.2 |
VEGF Antibody | |||
V8154-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis. |
VEGF Antibody | |||
V8154-20UG | NSJ Bioreagents | 20 ug | EUR 186.15 |
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis. |
VEGF Antibody | |||
V8154SAF-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis. |
Rat Monoclonal anti-mouse VEGF-D | |||
mAP-0007 | Angio Proteomie | 100ug | EUR 250 |